Alvin Shih

CIK 1610064 · EVP of Research & Development · last filed 2025-09-15

Alvin Shih is an EVP of Research & Development who has filed 12 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing shows the insider bought $157.8K of ZVRA on Sep 15, 2025. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $253.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$253.0K

Companies

2

Total Filings

12

Lifetime Open-Market Net

-$1.54M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ZVRA Director 20,000 $12.65 $253.0K $157.8K 4 2025-09-15
Travere Therapeutics, Inc. (RTRX) Delisted EVP of Research & Development 158,334 -$1.69M 8 2016-09-02

Recent Filings

12 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2025-09-15 ZVRA Buy (P) +20,000 $157.8K EDGAR
2025-05-30 ZVRA Grant (A) $0 EDGAR
2024-05-15 ZVRA Grant (A) $0 EDGAR
2024-02-02 ZVRA Grant (A) $0 EDGAR
2016-09-02 Travere Therapeutics, Inc. (RTRX) Delisted Sell (S) −8,750 -$142.1K EDGAR
2016-06-02 Travere Therapeutics, Inc. (RTRX) Delisted Sell (S) −8,750 -$155.3K EDGAR
2016-05-23 Travere Therapeutics, Inc. (RTRX) Delisted Grant (A) $0 EDGAR
2016-03-01 Travere Therapeutics, Inc. (RTRX) Delisted Sell (S) −8,750 -$125.6K EDGAR
2015-12-10 Travere Therapeutics, Inc. (RTRX) Delisted Sell (S) −8,750 -$182.3K EDGAR
2015-10-08 Travere Therapeutics, Inc. (RTRX) Delisted Sell (S) −8,750 -$176.1K EDGAR
Showing 110 of 12
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.